Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 7:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 142 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Huntington Disease Clear all
Completed Phase 2 Interventional

Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability

NCT01411163
View directory record Official record
Conditions
Huntington's Disease
Interventions
Creatine monohydrate
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
26 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Oct 4, 2026, 7:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Randomized Study of SPK-10001 Gene Therapy in Participants With Huntington's Disease

NCT06826612
View directory record Official record
Conditions
Huntington Disease
Interventions
SPK-10001, Placebo Surgery Control
Genetic · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2035
U.S. locations
5
States / cities
Boston, Massachusetts • Cincinnati, Ohio • Columbus, Ohio + 2 more
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Terminated Phase 2 Interventional Results available

Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021

NCT02342548
View directory record Official record
Conditions
Huntington's Disease
Interventions
20 mg BID of PF-02545920
Drug
Lead sponsor
Pfizer
Industry
Eligibility
30 Years to 66 Years
Enrollment
188 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
17
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Irvine, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2018 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 3 Interventional Results available

First Time Use of SD-809 in Huntington Disease

NCT01795859
View directory record Official record
Conditions
Chorea
Interventions
SD-809, Placebo
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Fayetteville, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2017 · Synced Oct 4, 2026, 7:07 AM EDT
Recruiting Phase 3 Interventional

A Study to Investigate the Efficacy, Safety and Tolerability of Votoplam in Participants With Huntington's Disease

NCT07326709
View directory record Official record
Conditions
Huntington Disease
Interventions
Votoplam (blinded), Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
21 Years to 70 Years
Enrollment
770 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
40
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 36 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed No phase listed Observational Results available

Impact of Xenazine(Tetrabenazine)on Gait and Functional Activity in Individuals With Huntington's Disease

NCT01451463
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Ohio State University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 2 Interventional Results available

A Phase 2, to Evaluating the Safety and Efficacy of Pridopidine Vs Placebo for Symptomatic Treatment in Patients With Huntington's Disease

NCT02006472
View directory record Official record
Conditions
Huntington's Disease
Interventions
Pridopidine, Placebo
Drug · Other
Lead sponsor
Prilenia
Industry
Eligibility
21 Years and older
Enrollment
408 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Englewood, Colorado + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Not applicable Interventional

Melatonin for Huntington's Disease (HD) Gene Carriers With HD Related Sleep Disturbance - a Pilot Study

NCT04421339
View directory record Official record
Conditions
Huntington Disease
Interventions
Melatonin, Placebo
Dietary Supplement · Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 3 Interventional

Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease

NCT04400331
View directory record Official record
Conditions
Chorea, Huntington
Interventions
Valbenazine
Drug
Lead sponsor
Neurocrine Biosciences
Industry
Eligibility
18 Years to 75 Years
Enrollment
154 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
31
States / cities
Birmingham, Alabama • Little Rock, Arkansas • La Jolla, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Child to Adult Neurodevelopment in Gene Expanded Huntington's Disease

NCT01860339
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
Peggy C Nopoulos
Other
Eligibility
6 Years to 30 Years
Enrollment
488 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2026
U.S. locations
6
States / cities
Sacramento, California • Iowa City, Iowa • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Not yet recruiting No phase listed Observational Accepts healthy volunteers

Multi-Modal Digital Monitoring of Disease Symptoms Huntington's Disease

NCT07315984
View directory record Official record
Conditions
Huntington Disease
Interventions
Not listed
Lead sponsor
BioSensics
Industry
Eligibility
25 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
2
States / cities
Rochester, New York • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 5, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 1 Interventional

Bioavailability of Ubiquinol in Huntington Disease

NCT00980694
View directory record Official record
Conditions
Huntington Disease
Interventions
ubiquinol
Dietary Supplement
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated May 27, 2016 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Non-Randomized, Open-Label, Single-Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of Dimebon [PF 01913539] In Subjects With Severely-Impaired And Normal Renal Function

NCT00824590
View directory record Official record
Conditions
Alzheimer's Disease, Huntington's Disease
Interventions
Dimebon
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
2
States / cities
Miami, Florida • Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 30, 2009 · Synced Oct 4, 2026, 7:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Retinal Imaging in Neurodegenerative Disease

NCT03233646
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment, Parkinson's Disease, Multiple Sclerosis, Huntington Disease, Lewy Body Dementia, Frontotemporal Dementia, Amyotrophic Lateral Sclerosis (ALS), APOE-4 Positive, Traumatic Brain Injury, Concussion, Post-Traumatic Stress Disorder, Down Syndrome, Neuro-Degenerative Disease, Normal Cognition
Interventions
Retinal and Choroidal Imaging
Device
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease

NCT04713982
View directory record Official record
Conditions
Huntington Disease
Interventions
Deutetrabenazine
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 1 Interventional Results available

Study to Measure Cerebrospinal Fluid Mutant Huntingtin Protein in Participants With Early Manifest Stage I or Stage II Huntington's Disease

NCT03664804
View directory record Official record
Conditions
Huntington's Disease
Interventions
No Study Drug was Administered in this Study
Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 65 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
6
States / cities
Englewood, Colorado • Washington D.C., District of Columbia • Wichita, Kansas + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2025 · Synced Oct 4, 2026, 7:07 AM EDT
Active, not recruiting Phase 2 Interventional

GENERATION HD2. A Study to Evaluate the Safety, Biomarkers, and Efficacy of Tominersen Compared With Placebo in Participants With Prodromal and Early Manifest Huntington's Disease

NCT05686551
View directory record Official record
Conditions
Huntington Disease
Interventions
Tominersen, Placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
25 Years to 50 Years
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed No phase listed Observational

FuRST 2.0 Cognitive Pre-Testing

NCT02881931
View directory record Official record
Conditions
Huntington's Disease
Interventions
FuRST 2.0
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
3
States / cities
Englewood, Colorado • Wichita, Kansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Oct 4, 2026, 7:07 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Genetic Risk: Whether, When, and How to Tell Adolescents

NCT03421327
View directory record Official record
Conditions
Huntington Disease, Hereditary Breast and Ovarian Cancer, Hereditary Cancer, Hereditary Non-polyposis Colon Cancer, Hereditary Non-Polyposis Colorectal Cancer Syndrome
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
15 Years and older
Enrollment
85 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Oct 4, 2026, 7:07 AM EDT
Completed No phase listed Observational

FuRST 2.0 Cognitive Pre-testing - Round 2

NCT03709173
View directory record Official record
Conditions
Huntington Disease
Interventions
FuRST 2.0
Behavioral
Lead sponsor
CHDI Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
3
States / cities
Englewood, Colorado • Wichita, Kansas • New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2019 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 2 Interventional

Safety and Tolerability Study of Phenylbutyrate in Huntington's Disease (PHEND-HD)

NCT00212316
View directory record Official record
Conditions
Huntington's Disease
Interventions
sodium phenylbutyrate
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
8
States / cities
Birmingham, Alabama • San Diego, California • Iowa City, Iowa + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2012 · Synced Oct 4, 2026, 7:07 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

HDClarity: a Multi-site Cerebrospinal Fluid Collection Initiative to Facilitate Therapeutic Development for Huntington's Disease

NCT02855476
View directory record Official record
Conditions
Huntington's Disease
Interventions
Not listed
Lead sponsor
University College, London
Other
Eligibility
11 Years to 75 Years
Enrollment
2,500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2017
U.S. locations
6
States / cities
Englewood, Colorado • Washington D.C., District of Columbia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Oct 4, 2026, 7:07 AM EDT
Completed Phase 2 Interventional

Effects of Lithium and Divalproex'on Brain-Derived Neurotrophic Factor in Huntington's Disease

NCT00095355
View directory record Official record
Conditions
Huntington's Disease
Interventions
Lithium, Divalproex
Drug
Lead sponsor
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Eligibility
Not listed
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 4, 2026, 7:07 AM EDT
Recruiting Not applicable Interventional

Home-based Transcranial Direct Current Stimulation Open Trial for Behavioral and Cognitive Symptoms in Huntington's Disease

NCT05326451
View directory record Official record
Conditions
Huntington Disease
Interventions
active tDCS
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 4, 2026, 7:07 AM EDT